Brief: Elicera Updates On Preclinical CAR T-Cell Program ELC-401 For Glioblastoma
Feb 27 (Reuters) - Elicera Therapeutics AB ELIC.ST: UPDATE ON PRECLINICAL CAR T-CELL PROGRAM ELC-401 FOR GLIOBLASTOMA: PRECLINICAL DEVELOPMENT CONCLUDED AND CLINICAL TRIAL PLANNING UNDERWAY Source text: ID:nWkr4w2JLd Further company coverage: ELIC.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Elicera Therapeutics Completes Phase I Part Of Carma Study
Brief: Elicera Therapeutics Gets Medical Products Agency Approval To Advance CARMA Study
Brief: Elicera Gets Clearance To Use Highest ELC-301 Dose Ahead Of Phase IIa
Brief: Elicera Gets First Patent Allowance For ELC-201
Brief: Elicera Receives Notice Of Allowance For U.S. Patent Application